Trial Profile
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate-067
- Sponsors Bristol-Myers Squibb
- 11 Sep 2023 Planned End Date changed from 29 Jan 2024 to 31 Oct 2024.
- 28 Jun 2023 Planned End Date changed from 16 Mar 2024 to 29 Jan 2024.
- 06 Jun 2023 Results assessing the validity of the same algorithm in two independent cohorts of melanoma patients enrolled in phase III trials CheckMate 067(NCT01844505) and CheckMate 238 (NCT02388906), presented at the 59th Annual Meeting of the American Society of Clinical Oncology.